Diagnostic value of D2-40 immunostaining for malignant mesothelioma: a meta-analysis

Chao He; Bo Wang; Chun Wan; Ting Yang; Yongchun Shen

doi:10.18632/oncotarget.19041

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Diagnostic value of D2-40 immunostaining for malignant mesothelioma: a meta-analysis

Chao He, Bo Wang, Chun Wan, Ting Yang and Yongchun Shen _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:64407-64416. https://doi.org/10.18632/oncotarget.19041

Metrics: PDF 1560 views | HTML 2615 views | ?

Abstract

Chao He1,*, Bo Wang2,*, Chun Wan3, Ting Yang3 and Yongchun Shen3

1Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu 610041, China

2Intensive Care Unit, West China Hospital of Sichuan University, Chengdu 610041, China

3Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu 610041, China

*These authors have contributed equally to this work

Correspondence to:

Yongchun Shen, email: [email protected]

Keywords: malignant mesothelioma, D2-40, diagnosis, meta-analysis

Received: March 10, 2017 Accepted: June 18, 2017 Published: July 06, 2017

ABSTRACT

Malignant mesothelioma (MM) has become a global disease burden for its rising incidence and invariable fatality. D2-40 has been widely used as an immunostaining marker of diagnosing MM, while its diagnostic value has not yet been evaluated. Our study aimed to assess the overall accuracy of D2-40 immunostaining for diagnosing MM through a meta-analysis. A total of 22 studies with 2,264 participants were identified from PubMed, EMBASE, Web of Science, Scopus and the Cochrane database. The pooled sensitivity and specificity of D2-40 for MM was 0.86 (95% CI: 0.84–0.89) and 0.77 (95% CI: 0.74–0.79), respectively. The area under the summary receiver operating characteristic curve is 0.93, with a diagnostic odds ratio 40.37 (95% CI: 19.97–81.61). None of the study variates was found to be a source of heterogeneity after meta-regression analysis. In conclusion, D2-40 immunostaining may not give sufficient evidence by itself to diagnose MM and should be in combination with other markers to improve the accuracy of diagnosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19041

Publication Alerts

Post-Publication Promotion

Publication Discount

Meta-Analysis:

Diagnostic value of D2-40 immunostaining for malignant mesothelioma: a meta-analysis

Abstract